Will KarXT (Cobenfy) receive EMA approval by September 26, 2025? | Binary | | | 3 months ago | |
Will Cobenfy achieve $1 billion in sales by the end of 2025? | Binary | | | 3 months ago | |
What will be Cobenfy's market share among schizophrenia treatments by the end of 2025? | Categorical | | | 3 months ago | |
Will Cobenfy receive a black box warning from the FDA by the end of 2025? | Binary | | | 3 months ago | |
Will Bristol Myers Squibb's stock price increase by more than 10% by the end of 2024? | Binary | | | 3 months ago | |
Will KarXT (Cobenfy) become the leading schizophrenia treatment in the U.S. by prescription volume by September 26, 2025? | Binary | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by the end of 2025? | Categorical | | | 3 months ago | |
What will be the peak annual sales of Cobenfy by the end of 2025? | Categorical | | | 3 months ago | |
How many new schizophrenia treatments will be approved by the FDA by September 26, 2025? | Categorical | | | 3 months ago | |
What sales milestone will KarXT (Cobenfy) achieve within the first year of launch? | Categorical | | | 3 months ago | |
Will KarXT (Cobenfy) achieve $500 million in sales within the first year of launch? | Binary | | | 3 months ago | |
What percentage of U.S. schizophrenia patients will be using KarXT (Cobenfy) by September 26, 2025? | Categorical | | | 3 months ago | |
